

# **Pediatrics Notes**

Department of Child Health School of Medical Sciences KNUST

2024-03-05

# Table of contents

|   |           |
|---|-----------|
| <b>Preface</b>                                | <b>7</b>  |
| <b>I History &amp; Examination</b>            | <b>8</b>  |
| 1 Child History and Examination               | 9         |
| 2 Neonatal History & Examination              | 10        |
| 3 Growth and Development                      | 11        |
| 4 Pediatric Anthropometry                     | 12        |
| <b>II Neonatology</b>                         | <b>13</b> |
| 5 Newborn Delivery and Resuscitation          | 14        |
| 6 Preterm and Low Birth Weight                | 15        |
| <b>7 Neonatal Jaundice</b>                    | <b>16</b> |
| 7.1 Introduction . . . . .                    | 16        |
| 7.2 Bilirubin metabolism . . . . .            | 16        |
| 7.3 Types of bilirubin . . . . .              | 17        |
| 7.4 Types of Jaundice . . . . .               | 17        |
| 7.4.1 Physiological jaundice . . . . .        | 17        |
| 7.4.2 Pathological jaundice . . . . .         | 18        |
| 7.5 Assessing for Neonatal Jaundice . . . . . | 19        |
| 7.6 Clinical features . . . . .               | 20        |
| 7.7 Management . . . . .                      | 20        |
| 7.7.1 Investigations . . . . .                | 21        |
| 7.7.2 Phototherapy . . . . .                  | 21        |
| 7.8 Long term complications . . . . .         | 23        |
| 7.9 Recommendations . . . . .                 | 23        |
| <b>8 Newborn Feeding</b>                      | <b>24</b> |

|  |               |
|--|---------------|
| <b>9 Neonatal Delivery Conditions</b>              | <b>25</b>     |
| 9.1 The health newborn . . . . .                   | 25            |
| 9.2 Occurrences at birth . . . . .                 | 25            |
| 9.3 Birth Asphyxia . . . . .                       | 25            |
| 9.3.1 Definition . . . . .                         | 25            |
| 9.3.2 Risk factors . . . . .                       | 26            |
| 9.3.3 Presentation . . . . .                       | 26            |
| 9.3.4 The APGAR Score . . . . .                    | 26            |
| 9.3.5 Management . . . . .                         | 27            |
| 9.3.6 Hypoxemic Ischaemic Encephalopathy . . . . . | 27            |
| <br><b>III Pulmonology</b>                         | <br><b>29</b> |
| <b>10 Respiratory Disorders I</b>                  | <b>30</b>     |
| <b>11 Respiratory Disorders II</b>                 | <b>31</b>     |
| <br><b>IV Cardiology</b>                           | <br><b>32</b> |
| <b>12 Anatomy, physiology &amp; Pathology</b>      | <b>33</b>     |
| 12.1 Anatomy, physiology and Pathology . . . . .   | 33            |
| <b>13 Evaluating Heart Diseases</b>                | <b>35</b>     |
| <b>14 Heart Failure</b>                            | <b>36</b>     |
| <b>15 Atrial Septal Defect</b>                     | <b>37</b>     |
| 15.2 Introducion . . . . .                         | 37            |
| 15.3 Pathophysiology . . . . .                     | 37            |
| 15.4 Clinical presentatoin . . . . .               | 37            |
| 15.5 Investigations . . . . .                      | 38            |
| 15.6 Natural history . . . . .                     | 38            |
| 15.7 Treatment . . . . .                           | 38            |
| 15.8 Prognosis . . . . .                           | 39            |
| <b>16 Ventricular Septal Defect</b>                | <b>40</b>     |
| <b>17 Patent Ductus Arteriosus</b>                 | <b>41</b>     |
| <b>18 Coarctation of the Aorta</b>                 | <b>42</b>     |
| <b>19 Tetralogy of Fallot</b>                      | <b>43</b>     |

|   |               |
|---|---------------|
| <b>20 Rheumatic Heart Disease</b>                     | <b>44</b>     |
| <b>21 Infective Endocarditis</b>                      | <b>45</b>     |
| <b>22 Endomyocardial Fibrosis</b>                     | <b>46</b>     |
| <b>23 Miscellaneous Conditions</b>                    | <b>47</b>     |
| <br><b>V Infectious Diseases</b>                      | <br><b>48</b> |
| <b>24 Immunodeficiencies</b>                          | <b>49</b>     |
| <b>25 HIV</b>   | <b>50</b>     |
| <b>26 Bacterial Sepsis &amp; UTI</b>                  | <b>51</b>     |
| <b>27 Tuberculosis</b>                                | <b>52</b>     |
| <b>28 Immunization</b>                                | <b>53</b>     |
| <b>29 Viral Infections</b>                            | <b>54</b>     |
| <br><b>VI Oncology</b>                                | <br><b>55</b> |
| <b>30 Pediatric Oncology I</b>                        | <b>56</b>     |
| <b>31 Pediatric Oncology II</b>                       | <b>57</b>     |
| <br><b>VII Nephrology</b>                             | <br><b>58</b> |
| <b>32 Hypertension</b>                                | <b>59</b>     |
| 32.1 The Concept of Blood Pressure . . . . .          | 59            |
| 32.2 Ways of measuring blood pressure . . . . .       | 59            |
| 32.3 Definition of Hypertension in children . . . . . | 60            |
| 32.4 Plotting the blood pressure centile . . . . .    | 60            |
| 32.5 Hypertensive emergency . . . . .                 | 61            |
| 32.6 Hypertensive Urgency . . . . .                   | 61            |
| 32.7 Rules of blood pressure measurement . . . . .    | 61            |
| 32.8 When to suspect hypertension . . . . .           | 62            |
| 32.9 Aetiology of hypertension . . . . .              | 62            |
| 32.9.1 Neonate to one-year . . . . .                  | 63            |
| 32.9.2 One- to five years . . . . .                   | 64            |

|  |           |
|--|-----------|
| 32.9.3 Five- to ten-years . . . . .                  | 64        |
| 32.9.4 Ten- to twenty-years . . . . .                | 64        |
| 32.10 Evaluation of the Hypertensive Child . . . . . | 64        |
| 32.11 Investigations . . . . .                       | 65        |
| 32.12 Uric Acid and hypertension . . . . .           | 66        |
| 32.13 Complication of Hypertension . . . . .         | 66        |
| 32.14 Treatment of hypertension . . . . .            | 66        |
| 32.14.1 Non-drug treatment . . . . .                 | 66        |
| 32.14.2 Drug Treatment . . . . .                     | 66        |
| 32.15 Hypertensive encephalopathy . . . . .          | 67        |
| <b>33 Renal Disorders</b>                            | <b>68</b> |
| <b>34 Nephrotic and Nephritic Syndrome</b>           | <b>69</b> |
| <b>35 Nephrotic and Nephritic Syndrome</b>           | <b>70</b> |
| <b>VIII Neurology</b>                                | <b>71</b> |
| <b>36 Cerebral Palsy</b>                             | <b>72</b> |
| <b>37 Seizure Disorders</b>                          | <b>73</b> |
| <b>38 Central Nervous System Disorders</b>           | <b>74</b> |
| <b>39 Neuromuscular Disorders</b>                    | <b>75</b> |
| <b>40 Neurocutaneous Syndromes</b>                   | <b>76</b> |
| <b>IX Endocrinology</b>                              | <b>77</b> |
| <b>41 Endocrine Disorders I</b>                      | <b>78</b> |
| <b>42 Endocrine Disorders II</b>                     | <b>79</b> |
| <b>43 Diabetes Mellitus</b>                          | <b>80</b> |
| <b>X Haematology</b>                                 | <b>81</b> |
| <b>44 Sickle Cell Disease</b>                        | <b>82</b> |
| <b>45 Anemia</b>                                     | <b>83</b> |

|  |           |
|--|-----------|
| <b>46 Bleeding Disorders</b>               | <b>84</b> |
| <b>XI Gastroenterology</b>                 | <b>85</b> |
| <b>47 Nutrition</b>                        | <b>86</b> |
| <b>48 Malnutrition</b>                     | <b>87</b> |
| <b>49 Liver Disorders</b>                  | <b>88</b> |
| <b>50 Prolonged Jaundice</b>               | <b>89</b> |
| <b>51 Diarrhoea Diseases</b>               | <b>90</b> |
| <b>52 Malaria</b>                          | <b>91</b> |
| <b>53 Infections and Infestations</b>      | <b>92</b> |
| <b>54 Dermatology</b>                      | <b>93</b> |
| <b>55 Therapeutics</b>                     | <b>94</b> |
| <b>56 Congenital Malformations</b>         | <b>95</b> |
| <b>57 Toxicology- &amp; Animal Bites</b>   | <b>96</b> |
| <b>58 Social, Ethical and Legal Issues</b> | <b>97</b> |
| <b>References</b>                          | <b>98</b> |

# Preface

This clinical note was put together by the Professors, Senior Lecturers and Lecturers in the Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology. Members of the Child Health Department include:

Prof Sampson Antwi  
Prof Daniel Ansong  
Prof Alex Osei-Akoto  
Prof Emmanuel O. A. Addo-Yobo  
Prof Joslin Alexei Dogbe  
Prof (Mrs) Gyikua Plange-Rhule  
Dr Samuel Blay Nguah  
Dr Emmanuel Ameyaw  
Dr Anthony Enimil  
Dr (Mrs) Vivian Paintsil  
Dr Serwaa Asafo-Agyei  
Dr Charles Hammond  
Dr (Mrs) Sandra Kwarteng Owusu  
Dr Adwoa Pokua Boakye Yiadom  
Dr Naana Ayiwa Wireko Brobby  
Dr (Mrs) Akua Afriyie Ocran

**Part I**

**History & Examination**



# **1 Child History and Examinaion**

## **2 Neonatal History & Examination**

## **3 Growth and Development**

## **4 Pediatric Anthropometry**

**Part II**

**Neonatology**

## **5 Newborn Delivery and Resuscitation**

## **6 Preterm and Low Birth Weight**

# 7 Neonatal Jaundice

## 7.1 Introduction

Jaundice is the yellowish discoloration of the skin, eyes and mucous membranes, caused by a pigment called bilirubin in the blood. Out of 10 term and 10 preterm infants, 6 and 8 of them will develop jaundice respectively, all in the 1st couple of weeks of life. Universally accepted as one of the commonest causes of admission and readmission in the first month of life. At KATH MBU, monthly admissions average between 300 and 400 and about 15 – 25% of all these admissions are cases of neonatal jaundice. Whereas the developed world describes kernicterus as a rare condition, unfortunately, the same cannot be said for us in developing countries. On average, cases of severe NNJ have ranged from 2.2% – 30.8% of all jaundice cases, with the monthly mortality from NNJ ranging from 2.8% - 15.2%. Remember, kernicterus is the only preventable cause of cerebral palsy!

## 7.2 Bilirubin metabolism

Humans continuously form bilirubin and the liver is the main organ responsible for the metabolism of bilirubin. For every gram of Hemoglobin, 35mg of bilirubin is produced. The bilirubin is conjugated by the UGT enzyme, making it water-soluble, which is then released into the bile before being excreted in the stool (and urine). It can also be broken down in the intestine by bacterial enzymes like *E. coli*. However, at birth, the newborn has several challenges. The liver is immature, and the levels of UGT are low. Newborns have  $\alpha$ -glucuronidase in the intestinal mucosa/brush border, which deconjugates the conjugated bilirubin found in the meconium. The unconjugated bilirubin can now be reabsorbed through the intestinal wall and recycled back into the circulation. This process is known as the “enterohepatic circulation of bilirubin”. The gut is sterile and, subsequently, infants have far fewer bacteria in the gut, and so very little, if any, bilirubin is reduced to urobilin and stercobilin.

### **Specifically to newborns**

More bilirubin is produced, on account of the short life span of Red Blood Cells and high Hemoglobin levels. The liver is immature. They also have fewer bacteria and low intestinal enzymatic activity in the intestine



## 7.3 Types of bilirubin

There are two types:

### **Unconjugated (Indirect) Bilirubin:**

This is lipid soluble, can cross the blood-brain barrier and is toxic in high amounts to the brain.

### **Conjugated (Direct) Bilirubin:**

This is water soluble, excreted in the urine and stool, and not toxic to the brain. However, high amounts could indicate underlying liver disease or injury.

In very high concentrations, unconjugated bilirubin, which is lipid soluble, is toxic to the developing brain. Once it crosses the blood-brain barrier and binds to brain tissue and deposits in the developing brain. Since this is an irreversible process, it leads to long-term neurological issues and even death.

## 7.4 Types of Jaundice

There are two main types of jaundice:

1. Physiological jaundice and
2. Pathological jaundice.

There are three main mechanisms for jaundice:

1. Increased bilirubin production
2. Decreased bilirubin clearance and
3. Increased enterohepatic circulation.

### 7.4.1 Physiological jaundice

#### **Increased bilirubin production:**

in term newborn infants, bilirubin production is 2 – 3x higher than in adults. This occurs because newborns have more RBCs and fetal RBCs have a shorter life span than those in adults. Unfortunately, the liver being immature, cannot conjugate and excrete all the bilirubin from the breakdown of all the excess RBCs, thereby resulting in spillover of bilirubin into the blood.

**Bilirubin clearance or excretion:**

This is decreased in newborns, mainly due to the low levels of the UGT enzyme in the liver. UGT activity in term infants at day 7 of age is approximately 1% of that of the adult liver and does not reach adult levels until about 14 weeks of age.

**Enterohepatic circulation:**

The presence of the  $\beta$ -glucuronidase results in an increase in the enterohepatic circulation of bilirubin, further increasing the bilirubin load in the infant. This is a diagnosis of exclusion

## 7.4.2 Pathological jaundice

**Definition**

Neonatal jaundice is said to be pathologic if:

- Jaundice in the 1st 24 - 48 hours of life.
- Rate of SB rise  $> 0.5$  mg/dL ( $8.5\mu\text{mol/L}$ ) per hour
- Jaundice all over the body (including palms & soles)
- Presence of a danger sign
- History of previous siblings having had jaundice at birth
- Jaundice in a term newborn after 2 weeks of age or in a preterm infant after 3 weeks of age
- Direct (conjugated) bilirubin concentration  $> 20\%$  of the total

It can be caused by certain pathologic conditions or exaggeration of the mechanisms responsible for physiologic neonatal jaundice. Identification of what is causing the jaundice is useful in guiding management, including counselling of the parents and what to expect for the next pregnancy. Most common cause is increased bilirubin production due to haemolytic disease processes that include the following:

- Isoimmune-mediated haemolysis (e.g., ABO or Rhesus D incompatibility)
- Erythrocyte enzymatic defects, e.g. G6PD deficiency
- Sepsis, especially Urinary Tract Infection
- Polycythaemia
- Birth Injuries resulting in sequestration of blood within a closed space, e.g. cephalohematoma, subgaleal bleed.

**ABO incompatibility**

This is one of the most common causes of isoimmune hemolytic disease during the neonatal period. Infants with blood group A or B, carried by blood group O mother, will have a positive antibody because of maternal anti-A or anti-B transfer into the fetal circulation.

### **Rhesus Incompatibility**

Rh incompatibility can occur when an Rh-negative pregnant mother is exposed to Rh-positive fetal red blood cells secondary to feto-maternal haemorrhage during pregnancy/delivery. As a result, the mother's blood gets exposed to the fetal circulation and sensitization occurs leading to maternal antibody production against the foreign Rh antigen. Once produced, maternal Rh (IgG) antibodies may cross freely from the placenta to the fetal circulation, where they form antigen-antibody complexes with Rh- positive fetal RBCs and eventually are destroyed, resulting in a fetal alloimmune-induced hemolytic anaemia and jaundice. The first pregnancy is usually not affected, but more antibodies are produced with each pregnancy making the jaundice worse with each pregnancy.

### **Decreased clearance or a reduction in the rate of excretion of bilirubin:**

Inherited defects in the gene that encodes the UGT liver enzyme (eg, Gilbert Syndrome), decrease bilirubin conjugation (eg Crigglar Najjar). In physiological jaundice, the levels are naturally low, but here, in addition to the low levels the UGT enzyme is either defective, absent or has a reduced function. This reduces hepatic bilirubin metabolism and its clearance thereby increasing the total serum unconjugated bilirubin levels.

### **Increased enterohepatic circulation**

The major causes are

- Breastfeeding jaundice
- Breast milk jaundice
- Impaired intestinal motility is caused by functional or anatomic obstruction.
- Congenital hypothyroidism also causes increased enterohepatic circulation on account of reduced gut motility.

## **7.5 Assessing for Neonatal Jaundice**

- Baby should be assessed in natural daylight
- Look for yellow eyes & skin, check the white part of the eyes only if the baby opens the eyes voluntarily.
- You may blanch the skin on the bridge of the nose or the palms/soles of the feet if they turn yellow...
- Remember that the yellowing spreads from head to toe...
- Do not rely on visual inspection alone to estimate the bilirubin level in a baby with jaundice!!! It can be very subjective!!

## 7.6 Clinical features

The clinical features of neonatal jaundice may include:

- Baby looks yellow! The yellowness appears cephalocaudal.
- May not be as active as he/she used to be
- Lethargic/hypotonic
- Weak cry, irritable
- Poor feeding
- High-pitched cry / poor cry
- Seizures
- Arching of the neck/back

Thus to evaluate a child with jaundice we:

- Determine birth weight, gestation and postnatal age (in hours)
- Assess clinical condition (well or ill)
- Degree of jaundice (visual inspection, SBR etc)
- Look for evidence of kernicterus / BIND

## 7.7 Management

The general principle of treatment includes

- Encourage frequent exclusive breastfeeding.
- Start Intravenous fluids only when there are signs of dehydration
- Watch out for danger signs
- Pathologic Neonatal jaundice is treated with
  - Phototherapy
  - Exchange Blood Transfusion (EBT)
  - Antibiotics

Be interested in the cause as this will serve as a guide in the management of the baby and direct your counselling as well as impact on subsequent pregnancies Loads of information in the maternal and child health record book, Gravidity and Parity, G6PD status, maternal Blood group & Rhesus status etc

### 7.7.1 Investigations

This should include but not be restricted to

- Serum Bilirubin (conjugated, unconjugated and total)
- Full Blood Count
- G6PD screening
- Blood Culture & Sensitivity
- Baby's blood group (only necessary if mother's blood group is O)
- Others include Direct Coomb's test, Urine C & S etc

### 7.7.2 Phototherapy

Phototherapy is the use of visible light to treat high levels of serum bilirubin in the newborn. The dose of phototherapy is a key factor in how quickly it works. The dose in turn is determined by:

- The wavelength of the light
- The intensity of the light (irradiance)
- The distance between the light and the baby
- The body's surface area is exposed to the light.

Effective phototherapy lowers serum bilirubin levels by converting the lipid-soluble bilirubin into water-soluble forms that can easily be excreted in the stool and urine. Phototherapy also prevents the need for an Exchange Blood Transfusion and prevents bilirubin from depositing in the brain. The breakdown of bilirubin begins almost instantaneously when the skin is exposed to light, hence, phototherapy should be started as early as possible.

**Initiating phototherapy** Always note the time the baby's SBR sample is being taken and estimate the age in hours up until that time. Interpret bilirubin levels according to the baby's postnatal age in hours and manage the bilirubin levels according to the threshold table. Start phototherapy if the SBR plots on or above the line appropriate for age (in hours) and gestational age. If the SBR plots just underneath the line, repeat the SBR after 6 hours or start phototherapy if a repeat is not feasible. Repeat the SBR at least 24 – 48 hours after initiation of phototherapy. Discontinue phototherapy when the SBR plots below the line.

#### Side effects

- Increase insensible water loss
- Loose stools
- Skin rash
- Bronze baby syndrome
- Hypo- or Hyperthermia

- Interruption of mother-baby bonding

##Sunlight Therapy Works for physiological jaundice, however, one can never tell by looking at a baby what kind of jaundice a baby has Err on the side of caution, at least always have the SBR checked first Remember prolonged exposure to UV rays can be harmful to the developing skin Baby cannot be put in the light for more than 30 minutes in a day Even most of the available literature and studies that recommend sunlight still advice that if the jaundice is severe, the baby must be managed in the hospital!! A serum bilirubin high enough to warrant treatment should be managed in the hospital.

##Exchange Blood Transfusion Provides a means of rapid reduction of circulating bilirubin in blood. Involves manual removal of the baby's blood and simultaneously replacing it with compatible donor blood In addition to reducing bilirubin levels EBT removes partially hemolyzed RBCs, RBCs coated with antibodies and circulating immunoglobulins.




Figure 7.1: Bilirubin Graph (> 38 weeks)

### Complications of Exchange Blood Transfusion

- Cardiac & respiratory disorders - Shock due to bleeding or inadequate replacement of blood
- infection - Catheter-related complications - Changes in the composition of the blood (high or low potassium, low calcium, low glucose, changes of pH) - Thrombocytopenia
- And the rare but serious complications of air embolism, portal hypertension, and necrotizing enterocolitis.

**Intravenous Immunoglobins** Treatment with intravenous immunoglobulin (IVIG) has been suggested as an alternative therapy to Exchange Blood Transfusion for isoimmune hemolytic

jaundice to reduce the need for Exchange Blood Transfusion and duration of phototherapy and hospitalization in isoimmune hemolytic disease of the newborn. It has been proposed that IVIG blocks the binding of the antibody to the antigen. With this blockade, hemolysis no longer occurs.

## **7.8 Long term complications**

The effects of bilirubin toxicity include

- Hearing loss
- Cerebral palsy
- Mental retardation
- Dental complications
- Delayed developmental milestones
- Seizure and visual disorders

## **7.9 Recommendations**

- Always err on the side of caution
- An SBR is always more objective
- Look out for danger signs
- As much breastmilk as possible by any means necessary
- Sunlight therapy is not recommended, if the baby is yellow enough for you to want to put him/her under the sun, then the baby needs to be brought to the hospital!

## **8 Newborn Feeding**



# 9 Neonatal Delivery Conditions

## 9.1 The health newborn

- Cries / Breathes normally
- Pink all over
- Well-flexed & moves all limbs spontaneously
- Suckles well at the breast
- Birth weight 2.5 – 4.0kg
- Normal vitals signs

## 9.2 Occurrences at birth

- The fluid in the alveoli is absorbed and replaced by air. If the transition is not smooth, it results in insufficient oxygen delivery to the vital organs...
- Poor muscle tone
- Respiratory distress or depression
- Slow heart rate
- Low BP
- Cyanosis

## 9.3 Birth Asphyxia

### 9.3.1 Definition

#### ! World Health Organisation definition

Birth Asphyxia is the medical condition resulting from deprivation of oxygen in the newborn that lasts long enough during the birth process to cause harm, usually to the brain.

### 9.3.2 Risk factors

Any condition that will lead to impairment of oxygenation or blood flow to the newborn's brain in the perinatal period. These include:

- Prolonged labour (CPD)
- Placental failure
- Cord around the neck
- Problems with oxygenation of maternal blood / maternal disease
- Anaemia and bleeding in the baby
- Congenital heart disease
- Infections
- Deficient medical skills and or knowledge

### 9.3.3 Presentation

The asphyxiated baby may have any of the following:

- Poor Apgar Scores
- May not cry at birth
- Floppy/spastic
- Breathing problems
- Unresponsive
- Seizures
- Irritable

### 9.3.4 The APGAR Score

It is an objective method of quantifying the newborn's condition. And is useful for conveying information about the newborn's overall status and response to resuscitation

Table 9.1: The APGAR Score

|                    | 0               | 1                    | 2                                  |
|--------------------|-----------------|----------------------|------------------------------------|
| <b>Heart Rate</b>  | 0               | <100                 | >=100                              |
| <b>Respiration</b> | 0               | Weak or Irregular    | Good Cry                           |
| <b>Reaction</b>    | None            | Slight               | Good                               |
| <b>Colour</b>      | Blue or<br>Pale | Pink body limbs blue | All pink                           |
| <b>Tone</b>        | Limp            | Some movement        | Active movement, limbs well flexed |

8-10 = No Asphyxia  
5-7 = Mild Asphyxia  
3-4 = Moderate Asphyxia  
0-2 = Severe Asphyxia

### 9.3.5 Management

- Largely supportive
- Newborn resuscitation/oxygenation
- Correction of fluid & electrolyte imbalances including shock
- Control of seizures
- Treatment of any underlying infection
- Look out for birth injuries
- Active cooling found to improve neurological outcome
- Temperature maintenance
- Full Blood Count, Culture & Sensitivity, Blood glucose etc
- Serum electrolytes: Na, K, Ca & Mg
- Start empiric 1st line antibiotics according to protocol: / X'pen & Gentamycin
- Start IV Fluids at 50ml/kg (Plain 10% Dextrose).
- Pass a urethral catheter and monitor the baby's urine output.
- The target temperature of the baby is 36.50C – 37.50C

### 9.3.6 Hypoxemic Ischaemic Encephalopathy

- The most important consequence of birth asphyxia is
- The outcome ranges from complete recovery to death
- 25 - 30% end up with permanent damage like Cerebral palsy & Mental retardation
- Prognosis dependent on gestational age, management of metabolic & cardiopulmonary complications & the severity of the encephalopathy
- Subsequent competent care and available facilities also influence the outcome

This is the first type of humeral fracture



Figure 9.1: Humeral Fracture (immobilised)

And this is another one



Figure 9.2: X-ray of a humeral fracture

**Part III**

**Pulmonology**

## **10 Respiratory Disorders I**

## **11 Respiratory Disorders II**

**Part IV**

**Cardiology**



# 12 Anatomy, physiology & Pathology

## 12.1 Anatomy, physiology and Pathology

The heart is located in the mediastinum of the chest, bounded anteriorly by the sternum, posteriorly by the spine and laterally by the lungs. Externally, the right ventricle is anterior. Most of the left ventricle, left atrium and right atrium are posterior. Internally the right and left atria are separated by the tricuspid and mitral valves respectively. The arterial supply of the heart is through the coronary arteries while venous drainage is through the coronary sinus. The aorta and pulmonary arteries arise from the left and right ventricles. The heart has three layers:

1. Endocardium: Inner epithelial layer of the heart
2. Myocardium: Muscular part of the heart
3. Pericardium: Outer layers of the heart. Divided into the visceral and parietal pericardium.

Venous blood enters the right atrium through the inferior and superior vena cavae. It empties in atrial systole into the right ventricle through the tricuspid valve. It then moves on through the pulmonary valve in ventricular systole, to the pulmonary artery and the lungs. Blood returning from the lungs enters the left atrium through the four pulmonary veins. In atrial systole, it moves onto the left ventricle through the mitral valve. Finally, it empties into the aorta through the aortic valve.

The heart has an inherent electrical system that automatically depolarises it. The parts are:

1. The SinoAtrial (SA) node: This is the pacemaker of the heart and depolarises the two atria.
2. AtrioVentricular (AV) node: Receives impulses from the SA node, delays a bit before propagating it further
3. His-purkinje fibre system. Responsible for the spread of electrical impulses to the ventricles

### Heart as a pump

There is a difference in the pumping action of the heart in utero and after birth.

1. Fetal
  - Most work is done by the Right ventricle

- The right Ventricle is therefore relatively hypertrophic
- Only 15% of the cardiac output is pumped into the lungs

## 2. After birth

- Gradual transition to Left ventricle dominance
- Gradual fall in pulmonary pressure (over 6 weeks)
- The left ventricle does most of the work and becomes thicker than the right

### **Systolic and diastolic functions**

*Systole:* This is the contractile phase of the heart. It starts with the atrium so it empties into the ventricles before the ventricle's subsequent contract.

*Diastole:* This is the relaxation phase where the heart relaxes and lets in blood. It also starts with the atrium and then the ventricles.

*Compliance:* This describes how easily the heart chamber relaxes in response to the inflow of blood.

### **Cardiac Pressures**

The pressures in the heart vary for different ages and individuals. Generally, the pressure in the atria are lower than that in the ventricles. Also, the pea systolic pressure in the left ventricle is higher than in the right. The diastolic pressure in the left ventricle is however lower than the right ventricle. In the typical adult heart, the following pressures are often observed. Also, both systolic and diastolic pressure in the aorta is higher than that in the pulmonary artery.

Systolic pressure in general is generated by the ventricles. In conditions such as coarctation of the aorta, aortic stenosis and pulmonary hypertension, the ventricles end up increasing their workload to generate enough pressure. The diastolic pressure on the other hand is maintained by the closure of the aortic and pulmonary valves. Thus incompetent pulmonary or aortic valve leads to a decrease in diastolic pressure in the the tow vessels respectively.

## **13 Evaluating Heart Diseases**

## **14 Heart Failure**

# 15 Atrial Septal Defect

## 15.1

## 15.2 Introduction

1. Defect in the inter-atrial septum
2. 5-10% of all CHD
3. Types
  - Secundum ASD (most common, 50-70%)
  - Primum ASD (30%)
  - Sinus venosus ASD
  - Coronary sinus ASD

## 15.3 Pathophysiology

- Left to right shunting and thus acyanotic
- leads to volume overload of the right atrium, ventricle, pulmonary artery and pulmonary oedema
- Consequent dilatation of the right atrium and ventricles
- Minimal pressure transmitted so no significant pressure overload
- Consequently, pulmonary oedema is usually insignificant
- Rarely have overt heart failure
- However, long-standing liaison or a very big lesion with a pulmonary-to-systemic flow ratio of 2 or more will lead to heart failure and pulmonary hypertension after about 15 to 20 years No Reversal of shunt

## 15.4 Clinical presentatoin

- Usually asymptomatic except for big lesion with high Qp: Qs
- They often have slender bodies

- Auscultation reveals a widely fixed split-second heart sound and a grade 2/6 to 3/6 ejection systolic murmur at the upper sternal border
- Many are almost silent, especially the small lesions which are often detected during an echocardiogram for another reason

## 15.5 Investigations

- Bedside SpO<sub>2</sub> is usually normal and hence an acyanotic heart disease
- In older patients, a chest x-ray may show
  - Cardiomegaly
  - Prominent pulmonary artery
  - Increased vascular markings
- The electrocardiogram may show
  - Right axis deviation due to the right ventricular dilatation
  - Right atrial enlargement
- An echocardiogram is diagnostic as it visualises the defect, and quantifies the shunt and other chamber sizes.
- Cardiac catheterization is often done in long-standing cases to detect complications that may have arisen.

## 15.6 Natural history

- Most ASDs will close spontaneously by 4 years, with smaller ones having a higher closure rate than bigger ones. A long-standing large defect however leads to chronic heart failure and pulmonary hypertension in early adulthood.
- Arrhythmias may arise because of the dilated right atrium.
- Though there are reported cases of paradoxical strokes in patients with ASDs, it remains an uncommon occurrence.
- Infective endocarditis is also rare in ASDs.

## 15.7 Treatment

There is no need for exercise restriction or prophylaxis for endocarditis. If there is no sign of heart failure, a device closure is often done after infancy or a surgical closure at 2-4 years of age. However, if there is heart failure, Medical treatment for heart failure is immediately instituted. Then a planned device closure or surgical closure can be done within the first year of life.

## 15.8 Prognosis

Prognosis is generally good with many living into adulthood even without corrective surgery. Post-surgical mortality is currently less than 0.5%. The patient will need very little long-term follow-up after the corrective surgery.

## **16 Ventricular Septal Defect**



## **17 Patent Ductus Arteriosus**

## **18 Coarctation of the Aorta**

## **19 Tetralogy of Fallot**

## **20 Rheumatic Heart Disease**

## **21 Infective Endocarditis**

## **22 Endomyocardial Fibrosis**

## **23 Miscellaneous Conditions**

**Part V**

**Infectious Diseases**



## **24 Immunodeficiencies**

## 25 HIV

## **26 Bacterial Sepsis & UTI**

## **27 Tuberculosis**

## 28 Immunization

## **29 Viral Infections**

# **Part VI**

## **Oncology**

## **30 Pediatric Oncology I**



## **31 Pediatric Oncology II**

**Part VII**

**Nephrology**

## 32 Hypertension

### 32.1 The Concept of Blood Pressure

Blood pressure is the force exerted by the blood against any unit area of the vessel wall. Physiologically,

$$BP = CO \times TPR = SV \times HR \times TPR$$

Where:

- *HR* is the Heart Rate
- *BP* is the Blood Pressure
- *TPR* is the Total Peripheral Resistance
- *CO* is the Cardiac Output
- *SV* is the stroke volume

### 32.2 Ways of measuring blood pressure

1. **Direct intra-arterial** measurements by placing a catheter into the vessel and measuring the pressure “in line” with the vessel (end-on-pressure). This method is used by physiologists and Intensivists. The principle is employed in the measurements of central venous pressure and intracranial pressure in clinical practice.
2. **The auscultatory method** is done with the use of a sphygmomanometer (either mercury or aneroid) and a stethoscope. This is the gold standard in clinical practice. Korotkoff sounds 1 and 5 sounds are measured for systolic and diastolic blood pressures respectively. Values obtained are generally lower than direct & oscillometric measurements.
3. **The palpation method** (flush technique) is performed with the use of a sphygmomanometer and palpating finger. Largely unreliable. Only systolic blood pressure can be measured with this technique. The palpated pulse is generally lower than Korotkoff sound 1 by 10mmHg.
4. **The oscillometric method** uses a sphygmomanometer and a monitor e.g. digital blood pressure devices and Dynamap. Here, pulsatile blood flow through arterial wall oscillations is transmitted to the cuff encircling the extremity. Korotkoff sound 1 is recorded at the point of rapid increase in oscillation amplitude. Korotkoff sound 5 is recorded as

the point of a sudden decrease in oscillation amplitude. Values obtained by oscillometric measurements are generally higher than auscultatory.

5. **Doppler ultrasound technique:** Here a Doppler ultrasound is held over the pulse to magnify the sound so that it is audible without a stethoscope. The sound detected may be 5mmHg higher than Korotkoff sound 1.
6. **Ambulatory blood pressure measurements.** Here, multiple measurements are recorded over time (e.g. 24 hours) with digital devices attached to the limb whilst the patient engages in normal activities outside the hospital. Results are analysed on a computer or paper tracer built into the device using the mean of the readings. It provides a truer picture of blood pressure trends useful in diagnosing “white coat hypertension” and nocturnal hypertension (absence of a normal physiological drop in blood pressure during sleep).

### 32.3 Definition of Hypertension in children

**In adults**, the epidemiological definition is based on the risk of adverse events (e.g. Stroke) being  $>140/90\text{mmHg}$ . **In children**, hypertension is defined statistically based on normative data: 95th centile for age, height, and gender (Refer to height centile chart and blood pressure levels). By this statistical definition, 5% of children will be classified as hypertensives. Other definitions include:

- **Normal blood pressure:**  $< 90\text{th}$  centile for age, height, and sex.
- **Pre-Hypertension:**  $90\text{th} - <95\text{th}$  centile for age, height, and sex
- **Stage 1 Hypertension:**  $95\text{th} - 99\text{th} + 5\text{ mmHg}$
- **Stage 2 Hypertension:**  $> 99\text{th centile} + 5\text{mmHg}$

A sample of the blood pressure chart is shown below.

### 32.4 Plotting the blood pressure centile

1. Measure the child's height
2. Determine the height centile. If the height centile falls between 2 centiles, use the closest centile. Otherwise, use the lower height centile.
3. Determine the blood pressure centile.
4. Classify blood pressure using the definitions above.

**Blood Pressure Levels for Boys by Age and Height Percentile (Continued)**

| Age<br>(Year) | BP<br>Percentile<br>↓ | Systolic BP (mmHg)       |      |      |      |      |      |      | Diastolic BP (mmHg)      |      |      |      |      |      |      |
|---------------|-----------------------|--------------------------|------|------|------|------|------|------|--------------------------|------|------|------|------|------|------|
|               |                       | ← Percentile of Height → |      |      |      |      |      |      | ← Percentile of Height → |      |      |      |      |      |      |
|               |                       | 5th                      | 10th | 25th | 50th | 75th | 90th | 95th | 5th                      | 10th | 25th | 50th | 75th | 90th | 95th |
| 11            | 50th                  | 99                       | 100  | 102  | 104  | 105  | 107  | 107  | 59                       | 59   | 60   | 61   | 62   | 63   | 63   |
|               | 90th                  | 113                      | 114  | 115  | 117  | 119  | 120  | 121  | 74                       | 74   | 75   | 76   | 77   | 78   | 78   |
|               | 95th                  | 117                      | 118  | 119  | 121  | 123  | 124  | 125  | 78                       | 78   | 79   | 80   | 81   | 82   | 82   |
|               | 99th                  | 124                      | 125  | 127  | 129  | 130  | 132  | 132  | 86                       | 86   | 87   | 88   | 89   | 90   | 90   |
| 12            | 50th                  | 101                      | 102  | 104  | 106  | 108  | 109  | 110  | 59                       | 60   | 61   | 62   | 63   | 63   | 64   |
|               | 90th                  | 115                      | 116  | 118  | 120  | 121  | 123  | 123  | 74                       | 75   | 75   | 76   | 77   | 78   | 79   |
|               | 95th                  | 119                      | 120  | 122  | 123  | 125  | 127  | 127  | 78                       | 79   | 80   | 81   | 82   | 82   | 83   |
|               | 99th                  | 126                      | 127  | 129  | 131  | 133  | 134  | 135  | 86                       | 87   | 88   | 89   | 90   | 90   | 91   |
| 13            | 50th                  | 104                      | 105  | 106  | 108  | 110  | 111  | 112  | 60                       | 60   | 61   | 62   | 63   | 64   | 64   |
|               | 90th                  | 117                      | 118  | 120  | 122  | 124  | 125  | 126  | 75                       | 75   | 76   | 77   | 78   | 79   | 79   |
|               | 95th                  | 121                      | 122  | 124  | 126  | 128  | 129  | 130  | 79                       | 79   | 80   | 81   | 82   | 83   | 83   |
|               | 99th                  | 128                      | 130  | 131  | 133  | 135  | 136  | 137  | 87                       | 87   | 88   | 89   | 90   | 91   | 91   |

Figure 32.1: Blood Pressure Centile Chart

## 32.5 Hypertensive emergency

This is an acutely elevated blood pressure with evidence of threatening end-organ damage involving the following organs:

- Brain (severe headache, visual changes, cranial nerve palsy, papilloedema)
- Heart (acute chest pain and tightness, shortness of breath)
- Kidney (decreased urine output acutely, proteinuria and haematuria on dipstick)

It is thus a symptomatic, severe Hypertension.

## 32.6 Hypertensive Urgency

This is severe hypertension without evidence of end-organ damage or symptoms. The blood pressure should nevertheless be treated urgently but not aggressively like in a hypertensive emergency to prevent progression into a hypertensive emergency. If possible, the patient should be managed as in-patient.

## 32.7 Rules of blood pressure measurement

1. Select the right cuff size
  - The length of the inflation bladder should be at least 80% of the mid-arm circumference.
  - The width of the inflation bladder is at least 40th of the mid-arm circumference.

2. The child should rest for at least 5 minutes in a comfortable environment and position.
3. Arm resting and supported at heart level (The reference level. Values outside this reference level are higher). The lower edge of the cuff is 2cm above the cubital fossa.
4. Bladder tubings should lie over the brachial artery.
5. Bell of the stethoscope is used
6. Korotkoff sounds 1 and 5 are used for systolic and diastolic respectively.
7. Multiple measurements are made (preferably at different settings) and the lowest reading is taken. For research purposes, 3 measurements are taken and an average of the last 2 used.

Blood pressure readings obtained in the legs are 10-20mmHg higher than the arm pressure in any individual. Arm blood pressure higher than leg blood pressure occurs in aortic coarctation distal to ductus arteriosus.

## 32.8 When to suspect hypertension

Suspect hypertension in any child with any of the following conditions:

- Alteration in consciousness including aggressive behavior and convulsion
- Oedematous
- Known kidney disease or evidence of abnormal urinalysis
- Heart failure
- Obesity
- Failure to thrive
- Stroke or other palsies including cranial nerve palsy
- History of Low Birth Weight (small number of nephrons)
- Unexplained anaemia, or blurred vision
- Neurofibromatosis
- Other syndromes like Turner & Williams

## 32.9 Aetiology of hypertension

Generally, childhood Hypertension is considered to be of secondary cause until proven otherwise. This is particularly so among the very young and the severely hypertensive. The majority (~80%) are of renal origin. However, the number of children with essential Hypertension is on the rise, particularly among obese adolescents and those with a positive family history.

Broadly, aetiology can be categorized into:

- Renal disease
- Vascular disorders

- Endocrine causes
- Neurologic causes
- Renal tumours
- Catecholamine-secreting tumours
- Drug-induced
- Miscellaneous causes

However, since these are often age-specific categorizations are done by age as below:

### **32.9.1 Neonate to one-year**

#### **Congenital**

- Congenital lesions of the vasculature
  - Renal Artery Stenosis
  - Aortic coarctation
- Congenital lesions of renal parenchyma
  - Polycystic Kidney disease
  - Dysplastic kidneys
  - Obstructive uropathy
- Congenital Adrenal Hyperplasia
  - 11- hydroxylase deficiency
  - 17- hydroxylase def

#### **Acquired**

- Renal artery or vein thrombosis secondary to umbilical artery or vein catheterisation
- Bronchopulmonary dysplasia
- Medications
  - Theophylline/caffeine
  - Phenylephrine and Ephedrine Nasal Drops in cold medications
  - Steroids
  - Vitamin D intoxication
- Total Parental Nutrition (high  $\text{Ca}^{2+}$ )
- Maternal drug use: Cocaine, heroin

### **32.9.2 One- to five years**

- Renal Artery Stenosis
- Glomerulonephritis
- Renal vein thrombosis
- Wilms tumour
- Neuroblastoma
- Pheochromocytoma
- Cystic kidney disease
- Monogenic Hypertension (e.g. Liddle's syndrome)

### **32.9.3 Five- to ten-years**

- Glomerulonephritis
- Renal scars from reflux nephropathies or Urinary Tract Infections
- Renal Artery Stenosis
- Cystic renal disease
- Endocrine tumours
- Essential Hypertension
- Obesity

### **32.9.4 Ten- to twenty-years**

- Obesity
- Essential hypertension
- Reflux nephropathies with repeated Urinary Tract Infections
- Glomerulonephritis
- Renal Artery Stenosis
- Endocrine tumours
- Hyperthyroidism
- Drugs (Oral Contraceptive Pill, illicit drugs)

## **32.10 Evaluation of the Hypertensive Child**

- Patient's history
- Symptoms of renal disease (haematuria, oliguria, evidence of bodily swelling, polyuria, enuresis)
- Symptoms of vasculitis or rheumatology ( Joint swelling & rash)
- Past medical history (umbilical artery/vein catheterisation, previous renal disease e.g. Previous swelling)



- Drug History (steroids, Oral Contraceptive Pill, amphetamines, other illicit drugs)
- Birth History: Low Birth Weight
- Family History of Hypertension

Clues on physical examination include:

- Coarctation of the Aorta & Takayasu:
  - Femoral artery delay or imperceptible
  - Blood pressure discrepancy between arm & leg → COA, Takayasu arteritis
- Neurofibromatosis
  - Café au lait spots
- RAS, Takayasu arteritis
  - Abdominal bruit
- Congenital adrenal hyperplasia
  - Ambiguous genitalia
- Dysmorphism suggestive of Turner or William syndromes
- Signs of Chronic Renal Failure: Growth failure (stunted), renal rickets, anaemia, oedema
- Bedside urine dipstick positive for protein and blood ( $\pm$  oedema)

## 32.11 Investigations

The rationale is 2-fold:

1. To define aetiology
2. To assess the presence of end-organ damage

Some of the investigations include:

- Full blood count
- Urine dipstick, microscopy and culture
- BUE, Serum Creatinine, Ca, Mg, PO<sub>4</sub>, blood gases
- Uric acid
- KUB ultrasound and Doppler studies to rule out Renal Artery Stenosis
- Chest X-ray for cardiomegaly
- Echocardiogram for Left Ventricular Hypertrophy (end organ damage)
- Fundoscopy
- Plasma Renin Activity (PRA) for RAS & renin secreting tumours
- Pre/post captopril nuclear scan

- MRA or CT Angiogram
- DMSA scan for renal scars
- Urine HVA & VMA for catechol amine secreting tumours/MIBG scintigraphy

## **32.12 Uric Acid and hypertension**

Uric acid is increasingly being implicated in the pathogenesis of Hypertension in both adults and children. It is believed to cause endothelial dysfunction leading to microvascular and inflammatory injury to the kidneys. There are also reduced levels of endothelial-derived nitric oxide and associated elevation of the Renin-Aldosterone-Angiotensin System. Elevated uric acid levels in hypertensive individuals are associated with adverse outcomes like stroke. Allopurinol treatment is advocated for such individuals.

## **32.13 Complication of Hypertension**

Some complications of Hypertension are listed below:

- Hypertensive encephalopathy
- Left Ventricular Failure
- Stroke
- Subarachnoid haemorrhage
- Secondary renal damage
- Retinopathy

## **32.14 Treatment of hypertension**

### **32.14.1 Non-drug treatment**

- Reducing salt intake
- Weight reduction for obesity-related hypertension
- Intake of more vegetables on account of potassium richness

### **32.14.2 Drug Treatment**

Principles of anti-hypertensive therapy:

- Long-acting (once-daily medication)
- Maximise treatment dosage before adding on

- Agents used will come from the “ABCD” group:
  - **A**CE inhibitor and ARBs (Avoid if RAS suspected or in hypovolaemia)
  - **B**eta-blocker
  - Calcium channel blocker
  - **D**iuretic
  - Every other drug (methyl dopa, alpha-blockers, vasodilators like hydralazine)

Generally, **A & B** drugs are not combined for Blood pressure control. Rather: **A + C + D** or **B + C + D**

## 32.15 Hypertensive encephalopathy

Hypertension with changes in mental status and/or seizures. Other manifestations are:

- Facial palsy
- Visual changes→blindness
- Coma

**Pathophysiology:** Disruption of the normal autoregulatory mechanisms of cerebral blood flow. The inability of cerebral vasculature to constrict appropriately in response to the abrupt increase in cerebral blood flow leads to cerebral hyperperfusion. Generally, short-acting anti-hypertensives are preferred in the initial instance of treatment so that any potentially harmful drop in blood pressure (which could lead to Posterior Reversible Encephalopathy Syndrome {PRES}) could be reversed. Subsequently, long-acting agents could be used Sublingual nifedipine could cause a precipitous drop in blood pressure so it is best avoided or should be used with extreme caution

Treatment outline:

- Use anti-hypertensive drugs
- Blood pressure should be brought down slowly to a desirable level (?stage I) by 48hrs (though not to normal levels) as follows:
  - 1/3 of total blood pressure reduction in 1st 12-hrs
  - Next one-third of the subsequent 12-hrs
  - Final one-third over 24-hrs
- Alternatively, by a quarter within 6 hours, and the rest in the next 24-36hrs

Commonly preferred drugs include Labetalol infusion, Na nitroprusside infusion, and IV hydralazine infusion. After achieving the desired blood pressure target, oral antihypertensives are then started

## **33 Renal Disorders**

## **34 Nephrotic and Nephritic Syndrome**

## **35 Nephrotic and Nephritic Syndrome**

**Part VIII**

**Neurology**

## **36 Cerebral Palsy**



## **37 Seizure Disorders**

## **38 Central Nervous System Disorders**

## **39 Neuromuscular Disorders**

## **40 Neurocutaneous Syndromes**

**Part IX**

**Endocrinology**

## **41 Endocrine Disorders I**

## **42 Endocrine Disorders II**

## **43 Diabetes Mellitus**



**Part X**

**Haematology**

## **44 Sickle Cell Disease**

## **45 Anemia**

## **46 Bleeding Disorders**

**Part XI**

**Gastroenterology**

## 47 Nutrition

## **48 Malnutrition**

## **49 Liver Disorders**



## **50 Prolonged Jaundice**

## **51 Diarrhoea Diseases**

## 52 Malaria

## **53 Infections and Infestations**

## **54 Dermatology**

## **55 Therapeutics**

## **56 Congenital Malformations**

## **57 Toxicology- & Animal Bites**



## **58 Social, Ethical and Legal Issues**

## References